45 related articles for article (PubMed ID: 38722325)
1. NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure.
Schmitt W; Diedrich C; Hamza TH; Meyer M; Eissing T; Breitenstein S; Rossano JW; Lipshultz SE
Pediatr Cardiol; 2024 May; ():. PubMed ID: 38722325
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
3. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
Tan ESJ; Chan SP; Liew OW; Chong JPC; Gerard Leong KT; Daniel Yeo PS; Ong HY; Jaufeerally F; Sim D; Ling LH; Lam CSP; Richards AM
JACC Heart Fail; 2024 Mar; 12(3):461-474. PubMed ID: 37897459
[TBL] [Abstract][Full Text] [Related]
4. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
6. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association.
Bogle C; Colan SD; Miyamoto SD; Choudhry S; Baez-Hernandez N; Brickler MM; Feingold B; Lal AK; Lee TM; Canter CE; Lipshultz SE;
Circulation; 2023 Jul; 148(2):174-195. PubMed ID: 37288568
[TBL] [Abstract][Full Text] [Related]
7. Heart Failure with Preserved Ejection Fraction in Children.
Das B; Deshpande S; Akam-Venkata J; Shakti D; Moskowitz W; Lipshultz SE
Pediatr Cardiol; 2023 Mar; 44(3):513-529. PubMed ID: 35978175
[TBL] [Abstract][Full Text] [Related]
8. Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP.
Palm J; Holdenrieder S; Hoffmann G; Hörer J; Shi R; Klawonn F; Ewert P
J Am Coll Cardiol; 2021 Nov; 78(19):1890-1900. PubMed ID: 34736565
[TBL] [Abstract][Full Text] [Related]
9. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
McDonagh TA; Metra M; Adamo M; Gardner RS; Baumbach A; Böhm M; Burri H; Butler J; Čelutkienė J; Chioncel O; Cleland JGF; Coats AJS; Crespo-Leiro MG; Farmakis D; Gilard M; Heymans S; Hoes AW; Jaarsma T; Jankowska EA; Lainscak M; Lam CSP; Lyon AR; McMurray JJV; Mebazaa A; Mindham R; Muneretto C; Francesco Piepoli M; Price S; Rosano GMC; Ruschitzka F; Kathrine Skibelund A;
Eur Heart J; 2021 Sep; 42(36):3599-3726. PubMed ID: 34447992
[No Abstract] [Full Text] [Related]
10. Pediatric and adult dilated cardiomyopathy are distinguished by distinct biomarker profiles.
Gropler MRF; Lipshultz SE; Wilkinson JD; Towbin JA; Colan SD; Canter CE; Lavine KJ; Simpson KE
Pediatr Res; 2022 Jul; 92(1):206-215. PubMed ID: 34404929
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis.
Buchan TA; Ching C; Foroutan F; Malik A; Daza JF; Hing NNF; Siemieniuk R; Evaniew N; Orchanian-Cheff A; Ross HJ; Guyatt G; Alba AC
Heart Fail Rev; 2022 Mar; 27(2):645-654. PubMed ID: 34227029
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of Pediatric Heart Failure in the USA-a 15-Year Multi-Institutional Study.
Morales-Demori R; Montañes E; Erkonen G; Chance M; Anders M; Denfield S
Pediatr Cardiol; 2021 Aug; 42(6):1297-1307. PubMed ID: 33871685
[TBL] [Abstract][Full Text] [Related]
13. NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Schmitt W; Rühs H; Burghaus R; Diedrich C; Duwal S; Eissing T; Garmann D; Meyer M; Ploeger B; Lippert J
Clin Pharmacol Ther; 2021 Aug; 110(2):498-507. PubMed ID: 33630302
[TBL] [Abstract][Full Text] [Related]
14. Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome.
van der Meulen M; den Boer S; du Marchie Sarvaas GJ; Blom N; Ten Harkel ADJ; Breur HMPJ; Rammeloo LAJ; Tanke R; Bogers AJJC; Helbing WA; Boersma E; Dalinghaus M
ESC Heart Fail; 2021 Apr; 8(2):1472-1481. PubMed ID: 33547769
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction.
Huusko J; Purmonen T; Toppila I; Lassenius M; Ukkonen H
ESC Heart Fail; 2020 Jun; 7(3):1039-1048. PubMed ID: 32187879
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Biomarkers in Pediatric Cardiomyopathy: Study Design and Recruitment Results from the Pediatric Cardiomyopathy Registry.
Everitt MD; Wilkinson JD; Shi L; Towbin JA; Colan SD; Kantor PF; Canter CE; Webber SA; Hsu DT; Pahl E; Addonizio LJ; Dodd DA; Jefferies JL; Rossano JW; Feingold B; Ware SM; Lee TM; Godown J; Simpson KE; Sleeper LA; Czachor JD; Razoky H; Hill A; Westphal J; Molina KM; Lipshultz SE;
Prog Pediatr Cardiol; 2019 Jun; 53():1-10. PubMed ID: 31745384
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
